v2.3.0.11
Acquisition of King Pharmaceuticals Inc - Pro Forma Information (Detail) (King [Member], Pro Forma Consolidated Results [Member], USD $)
In Millions, except Per Share data
3 Months Ended 6 Months Ended
Jul. 04, 2010
Jul. 03, 2011
Jul. 04, 2010
King [Member] | Pro Forma Consolidated Results [Member]
     
Business Acquisition [Line Items]      
Revenues $ 17,465 $ 33,595 $ 34,414
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 2,408 $ 5,008 $ 4,314
Diluted earnings per share attributable to Pfizer Inc. common shareholders $ 0.30 $ 0.63 $ 0.53